The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A Novel Augmentation Strategy for Treating Resistant Major Depression
Abstract
OBJECTIVE: Treatment-resistant depression is a significant public health concern; drug switching or augmentation often produce limited results. The authors hypothesized that fluoxetine could be augmented with olanzapine to successfully treat resistant depression. METHOD: An 8-week double-blind study was conducted with 28 patients who were diagnosed with recurrent, nonbipolar, treatment-resistant depression without psychotic features. Subjects were randomly assigned to one of three groups: olanzapine plus placebo, fluoxetine plus placebo, or olanzapine plus fluoxetine. RESULTS: Fluoxetine monotherapy produced minimal improvement on various scales that rate severity of depression. The benefits of olanzapine monotherapy were modest. Olanzapine plus fluoxetine produced significantly greater improvement than either monotherapy on one measure and significantly greater improvement than olanzapine monotherapy on the other measures after 1 week. There were no significant differences between treatment groups on extrapyramidal measures nor significant adverse drug interactions. CONCLUSIONS: Olanzapine plus fluoxetine demonstrated superior efficacy for treating resistant depression compared to either agent alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Research works printed but not linked: 16
- Amsterdam JD, Hornig-Rohan M: Treatment algorithms in treatment-resistant depression. Psychiatr Clin North Am 1996; 19:371–386 · DOI
- Fawcett J: Progress in treatment-resistant and treatment-refractory depression: we still have a long way to go. J Clin Psychiatry 1994; 24:214–216 · DOI
- Roose SP, Glassman AH, Walsh BT, Woodring S: Tricyclic nonresponders: phenomenology and treatment. Am J Psychiatry 1986; 143:345–348 · DOI
- Robertson MM, Trimble MR: Major tranquillisers used as antidepressants: a review. J Affect Disord 1982; 4:173–193 · DOI
- Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT: Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 1993; 54:338–342
- Spiker DG, Weiss JC, Dealy RS, Griffin SJ, Hanin I, Neil NF, Perel JM, Rossi AJ, Soloff PH: The pharmacological treatment of delusional depression. Am J Psychiatry 1985; 142:430–436
- Wolfersdorf M, Barg T, Konig F, Leibfarth M, Grunewald I: Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use. Pharmacopsychiatry 1995; 28:56–60 · DOI
- Wolfersdorf M, Konig F, Straub R: Pharmacotherapy of delusional depression: experience with combinations of antidepressants with the neuroleptics zotepine and haloperidol. Neuropsychobiology 1994; 29:189–193 · DOI
- Casey DE: Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. Psychiatr Clin North Am 1993; 16:589–610 · DOI
- Jeste DV, Caligiuri MP: Tardive dyskinesia. Schizophr Bull 1993; 19:303–315 · DOI
- Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH, Kiesler GM: Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997; 58:205–211 · DOI
- Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH: Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997; 154:1248–1254 · DOI · Paper page
- Gillings D, Koch G: The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Info J 1991; 25:411–425 · DOI
- Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong TD: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14:87–96 · DOI · Paper page
- Zhang W, Perry WK, Wong DT, Potts BD, Bao J, Tollefson GD, Bymaster FP: Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000; 23:250–262 · DOI
- Knable MB, Weinberger DR: Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol 1997; 11:123–131 · DOI · Paper page
Cited by
Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Self-citationDopamine system dysregulation in major depressive disorders
Belujon, P., & Grace, A. A. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx056 · Cited by 754
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300059 · Cited by 580
Nelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552
Metadata
- Authors
- Shelton, R. C., Tollefson, G. D., Tohen, M., Stahl, S., Gannon, K. S., Jacobs, T. G., Buras, W. R., Bymaster, F. P., Zhang, W., Spencer, K. A., Feldman, P. D., & Meltzer, H. Y.
- Venue
- American Journal of Psychiatry
- Published
- 2001-01-01
- Volume
- 158
- Issue
- 1
- Pages
- 131-134
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2114693958
- Cited by
- 504
- References
- 2
- FWCI
- 28.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
